Download presentation
Presentation is loading. Please wait.
Published byPearl Edwards Modified over 6 years ago
1
Biomarker-Guided HF Therapy: Is It Cost-Effective?
2
Age-Adjusted Hospitalization Rates for Heart Failure
3
Cost* of Heart Failure to Society
4
Diagnostic Uncertainty Is Associated With Poor Prognosis in Acute Dyspnea
6
Effect of Selective NT-proBNP Testing on Costs Results of the Randomized IMPROVE-CHF Trial
7
ADHERE: Time From BNP to Time to Diuretic Treatment
8
OPTIMIZE-HF BNP Measures and Death and Hospitalization at 1 Year
9
Therapies With Effects on B-Type Natriuretic Peptide Levels
10
IMPROVE HF: Improvement in Quality Measures at 24 Months (Patient Level Analysis)
11
PROTECT: Primary Endpoint Reduction
12
Cost-Effectiveness TIME-CHF Mortality in Reduced LVEF
13
Biomarker -Guided Heart Failure Trials
14
GUIDE-IT
15
Challenges/Opportunities for Utilizing Biomarkers in the Management of Heart Failure
16
Thank you for joining us for this program. So, what would you do
Thank you for joining us for this program. So, what would you do? What impact does this program on biomarkers have on your practice? As a reminder please join me on Medscape Discuss, a supplementary discussion by clicking the Join the Discussion button now. I am interested in hearing your thoughts and questions around this topic.
Similar presentations
© 2025 SlidePlayer.com Inc.
All rights reserved.